HK1085511A1 - Complement inhibitors from ticks - Google Patents
Complement inhibitors from ticksInfo
- Publication number
- HK1085511A1 HK1085511A1 HK06105580.9A HK06105580A HK1085511A1 HK 1085511 A1 HK1085511 A1 HK 1085511A1 HK 06105580 A HK06105580 A HK 06105580A HK 1085511 A1 HK1085511 A1 HK 1085511A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- complement inhibitors
- ticks
- complement
- relates
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
- G01N2333/43556—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from ticks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/42—Poisoning, e.g. from bites or stings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0312619A GB0312619D0 (en) | 2003-06-02 | 2003-06-02 | Complement inhibitors |
GB0327386A GB0327386D0 (en) | 2003-11-25 | 2003-11-25 | Complement inhibitors |
PCT/GB2004/002341 WO2004106369A2 (en) | 2003-06-02 | 2004-06-02 | Complement inhibitors from ticks |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1085511A1 true HK1085511A1 (en) | 2006-08-25 |
Family
ID=33492257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06105580.9A HK1085511A1 (en) | 2003-06-02 | 2006-05-15 | Complement inhibitors from ticks |
Country Status (13)
Country | Link |
---|---|
US (5) | US7884188B2 (ja) |
EP (1) | EP1629098B1 (ja) |
JP (1) | JP4772667B2 (ja) |
AT (1) | ATE427356T1 (ja) |
AU (1) | AU2004242759B2 (ja) |
BR (1) | BRPI0410876B8 (ja) |
CA (1) | CA2526083C (ja) |
DE (1) | DE602004020334D1 (ja) |
ES (1) | ES2324993T3 (ja) |
HK (1) | HK1085511A1 (ja) |
MX (1) | MXPA05012880A (ja) |
NZ (1) | NZ544163A (ja) |
WO (1) | WO2004106369A2 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1629098B1 (en) * | 2003-06-02 | 2009-04-01 | Varleigh Limited | Complement inhibitors from ticks |
BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
US8088579B2 (en) | 2005-02-14 | 2012-01-03 | University Of Iowa Research Foundation | Complement factor H for diagnosis of age-related macular degeneration |
EP1885398B1 (en) | 2005-05-26 | 2015-07-08 | The Regents of the University of Colorado, a body corporate | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
NZ568384A (en) | 2005-12-12 | 2011-09-30 | Ac Immune Sa | Therapeutic vaccine comprising Abeta peptide |
CA2662716C (en) * | 2006-09-08 | 2017-11-21 | Varleigh Limited | Method of treating respiratory disorders |
GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
PL2148691T3 (pl) * | 2007-02-05 | 2015-12-31 | Apellis Pharmaceuticals Inc | Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego |
WO2008140653A2 (en) | 2007-03-14 | 2008-11-20 | Taligen Therapeutics, Inc. | Humaneered anti-factor b antibody |
GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
US20090324585A1 (en) * | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
CN101928709B (zh) * | 2009-06-24 | 2012-05-23 | 中国农业科学院上海兽医研究所 | 一种亚洲璃眼蜱的组胺结合蛋白HaHBP的基因序列和重组表达与应用 |
AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
CA2785612C (en) * | 2010-01-08 | 2019-09-10 | Varleigh Immuno Pharmaceuticals (Vip) Ltd. | Ev576 for use in the treatment of viral infections of the respiratory tract |
CA2792622A1 (en) | 2010-03-11 | 2011-09-15 | University Of Louisville Research Foundation, Inc. | Methods of predicting and decreasing the risk of pregnancy loss |
WO2012078968A2 (en) | 2010-12-10 | 2012-06-14 | Lifeline Scientific, Inc. | Machine perfusion with complement inhibitors |
US8961981B2 (en) * | 2011-06-20 | 2015-02-24 | Saint Louis University | Targeting the neuromuscular junction for treatment |
MX363606B (es) | 2011-06-22 | 2019-03-28 | Apellis Pharmaceuticals Inc | Uso de inhibidores del complemento en trastornos crónicos. |
AU2013222836B2 (en) | 2012-02-20 | 2017-07-20 | Swedish Orphan Biovitrum Ab (Publ) | Polypeptides binding to human complement C5 |
EP2855529A4 (en) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | HUMANIZED ANTI-FACTOR B ANTIBODIES |
GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
GB201602802D0 (en) | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
US20200325449A1 (en) | 2016-06-02 | 2020-10-15 | The Cleveland Clinic Foundation | Complement inhibition for improving cell viability |
KR102534895B1 (ko) | 2016-06-14 | 2023-05-24 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 및 이의 용도 |
GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
EP4275696A1 (en) | 2017-04-21 | 2023-11-15 | Volution Immuno Pharmaceuticals SA | Coversin for the treatment of autoimmune blistering diseases |
AU2018383751A1 (en) | 2017-12-13 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
EP3849588A1 (en) | 2018-09-10 | 2021-07-21 | Volution Immuno Pharmaceuticals SA | Coversin for use in the treatment of rheumatic diseases |
GB201905810D0 (en) | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
EP4034237A1 (en) | 2019-09-27 | 2022-08-03 | Volution Immuno Pharmaceuticals SA | Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3734093A (en) * | 1992-02-27 | 1993-09-13 | Merck & Co., Inc. | Protein for inhibiting collagen-stimulated platelet aggregation |
US7884066B2 (en) * | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
EP1629098B1 (en) * | 2003-06-02 | 2009-04-01 | Varleigh Limited | Complement inhibitors from ticks |
-
2004
- 2004-06-02 EP EP04735758A patent/EP1629098B1/en not_active Expired - Lifetime
- 2004-06-02 MX MXPA05012880A patent/MXPA05012880A/es not_active Application Discontinuation
- 2004-06-02 AT AT04735758T patent/ATE427356T1/de active
- 2004-06-02 BR BRPI0410876A patent/BRPI0410876B8/pt active IP Right Grant
- 2004-06-02 ES ES04735758T patent/ES2324993T3/es not_active Expired - Lifetime
- 2004-06-02 AU AU2004242759A patent/AU2004242759B2/en not_active Expired
- 2004-06-02 DE DE602004020334T patent/DE602004020334D1/de not_active Expired - Lifetime
- 2004-06-02 NZ NZ544163A patent/NZ544163A/en unknown
- 2004-06-02 US US10/558,937 patent/US7884188B2/en active Active
- 2004-06-02 CA CA2526083A patent/CA2526083C/en not_active Expired - Lifetime
- 2004-06-02 WO PCT/GB2004/002341 patent/WO2004106369A2/en active Application Filing
- 2004-06-02 JP JP2006508386A patent/JP4772667B2/ja not_active Expired - Lifetime
-
2006
- 2006-05-15 HK HK06105580.9A patent/HK1085511A1/xx unknown
-
2011
- 2011-02-07 US US12/931,640 patent/US8993264B2/en active Active
-
2015
- 2015-02-18 US US14/624,909 patent/US9834585B2/en not_active Expired - Lifetime
-
2017
- 2017-08-17 US US15/679,425 patent/US20180127472A1/en not_active Abandoned
-
2022
- 2022-01-05 US US17/569,374 patent/US20220363726A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ATE427356T1 (de) | 2009-04-15 |
DE602004020334D1 (de) | 2009-05-14 |
US8993264B2 (en) | 2015-03-31 |
US7884188B2 (en) | 2011-02-08 |
JP2007536894A (ja) | 2007-12-20 |
CA2526083A1 (en) | 2004-12-09 |
EP1629098B1 (en) | 2009-04-01 |
US20070141573A1 (en) | 2007-06-21 |
BRPI0410876A (pt) | 2006-07-04 |
BRPI0410876B8 (pt) | 2023-01-24 |
US20160096870A1 (en) | 2016-04-07 |
EP1629098A2 (en) | 2006-03-01 |
ES2324993T3 (es) | 2009-08-21 |
JP4772667B2 (ja) | 2011-09-14 |
CA2526083C (en) | 2017-01-17 |
US20220363726A1 (en) | 2022-11-17 |
WO2004106369A2 (en) | 2004-12-09 |
AU2004242759A1 (en) | 2004-12-09 |
US9834585B2 (en) | 2017-12-05 |
AU2004242759B2 (en) | 2009-11-26 |
MXPA05012880A (es) | 2006-02-22 |
WO2004106369A3 (en) | 2005-02-17 |
NZ544163A (en) | 2009-06-26 |
BRPI0410876B1 (pt) | 2020-11-03 |
US20110263482A1 (en) | 2011-10-27 |
US20180127472A1 (en) | 2018-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1085511A1 (en) | Complement inhibitors from ticks | |
TNSN05044A1 (en) | Use of ikappab kinase inhibitors for the treatment of pain | |
WO2003105840A3 (en) | SPHINGOSINE KINASE INHIBITORS | |
GB0223040D0 (en) | Therapeutic compounds | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
MY158162A (en) | 5-membered heterocycle-based p38 kinase inhibitors | |
NO20034056D0 (no) | Proliferative sykdommer | |
MXPA05012812A (es) | Compuestos, metodos y composiciones farmaceuticas para inhibir poli(adenosina-5'-difosfo-ribosa)polimerasa(parp). | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
DK1420801T3 (da) | Anvendelse af fucaner til behandling af adhæsioner, arthritis og psoreasis | |
HRP20130602T1 (en) | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases | |
MXPA04008772A (es) | Composiciones de clorhidrato de naltrexona. | |
PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
IS7669A (is) | Aðferðir til að meðhöndla eða fyrirbyggja með 2,4-pyrímidíndíamín efnasamböndum sjálfsónæmissjúkdóma | |
NO20055612L (no) | Anti-inflammatoriske fosfonatforbindelser | |
TW200509949A (en) | Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents | |
EP1553951A4 (en) | COMPOSITIONS CONTAINING A JNK INHIBITOR FOR TREATING, PREVENTING, MANAGING AND / OR MODIFYING PAIN, AND METHODS OF USE THEREOF | |
DK1581235T3 (da) | Anvendelse af spongosin (2-methoxyadenosin) til behandling af smerte i særdeleshed hyperalgesi | |
HK1082923A1 (en) | Synergistic compositions for the prevention and treatment of acquired immunodeficiency | |
EP1667976A4 (en) | Isoquinolinone POTASSIUM CHANNEL INHIBITORS | |
DE60329326D1 (de) | Tace inhibitoren | |
MXPA05011699A (es) | Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior. | |
WO2004060878A3 (en) | Inhibitors of phosphatases | |
HUP0401633A2 (hu) | Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására | |
WO2003072053A3 (en) | Compounds for treatment of copper overload |